FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361954246> ?p ?o ?g. }

• W4361954246 abstract "<div>AbstractPurpose:<p>We hypothesized that resistance to hypomethylating agents (HMA) among patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) would be overcome by combining a programmed death-ligand 1 antibody with an HMA.</p>Patients and Methods:<p>We conducted a Phase I/II, multicenter clinical trial for patients with MDS not achieving an International Working Group response after at least 4 cycles of an HMA (“refractory”) or progressing after a response (“relapsed”) with 3+ or higher risk MDS by the revised International Prognostic Scoring System (IPSS-R) and CMML-1 or -2. Phase I consisted of a 3+3 dose-escalation design beginning with guadecitabine at 30 mg/m² and escalating to 60 mg/m² Days 1 to 5 with fixed-dose atezolizumab: 840 mg intravenously Days 8 and 22 of a 28-day cycle. Primary endpoints were safety and tolerability; secondary endpoints were overall response rate (ORR) and survival.</p>Results:<p>Thirty-three patients, median age 73 (range 54–85), were treated. Thirty patients had MDS and 3 had CMML, with 30% relapsed and 70% refractory. No dose-limiting toxicities were observed in Phase I. There were 3 (9%) deaths in ≤ 30 days. Five patients (16%) came off study for drug-related toxicity. Immune-related adverse events (IRAE) occurred in 12 (36%) patients (4 grade 3, 3 grade 2, and 5 grade1). ORR was 33% [95% confidence interval (CI), 19%–52%] with 2 complete remission (CR), 3 hematologic improvement, 5 marrow CR, and 1 partial remission. Median overall survival was 15.1 (95% CI, 8.5–25.3) months.</p>Conclusions:<p>Guadecitabine with atezolizumab has modest efficacy with manageable IRAEs and typical cytopenia-related safety concerns for patients with relapsed or refractory MDS and CMML.</p></div>" @default.
• W4361954246 created "2023-04-05" @default.
• W4361954246 creator A5004854900 @default.
• W4361954246 creator A5008135649 @default.
• W4361954246 creator A5008481807 @default.
• W4361954246 creator A5013538977 @default.
• W4361954246 creator A5013923213 @default.
• W4361954246 creator A5018403340 @default.
• W4361954246 creator A5018798845 @default.
• W4361954246 creator A5020254333 @default.
• W4361954246 creator A5026989385 @default.
• W4361954246 creator A5030941347 @default.
• W4361954246 creator A5033440492 @default.
• W4361954246 creator A5043864217 @default.
• W4361954246 creator A5049910941 @default.
• W4361954246 creator A5052288829 @default.
• W4361954246 creator A5054876564 @default.
• W4361954246 creator A5056577241 @default.
• W4361954246 creator A5058612163 @default.
• W4361954246 creator A5062167990 @default.
• W4361954246 creator A5062542207 @default.
• W4361954246 creator A5062941900 @default.
• W4361954246 creator A5064201088 @default.
• W4361954246 creator A5079310177 @default.
• W4361954246 creator A5088347458 @default.
• W4361954246 date "2023-04-01" @default.
• W4361954246 modified "2023-10-18" @default.
• W4361954246 title "Data from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine" @default.
• W4361954246 doi "https://doi.org/10.1158/1078-0432.c.6533007.v1" @default.
• W4361954246 hasPublicationYear "2023" @default.
• W4361954246 type Work @default.
• W4361954246 citedByCount "0" @default.
• W4361954246 crossrefType "posted-content" @default.
• W4361954246 hasAuthorship W4361954246A5004854900 @default.
• W4361954246 hasAuthorship W4361954246A5008135649 @default.
• W4361954246 hasAuthorship W4361954246A5008481807 @default.
• W4361954246 hasAuthorship W4361954246A5013538977 @default.
• W4361954246 hasAuthorship W4361954246A5013923213 @default.
• W4361954246 hasAuthorship W4361954246A5018403340 @default.
• W4361954246 hasAuthorship W4361954246A5018798845 @default.
• W4361954246 hasAuthorship W4361954246A5020254333 @default.
• W4361954246 hasAuthorship W4361954246A5026989385 @default.
• W4361954246 hasAuthorship W4361954246A5030941347 @default.
• W4361954246 hasAuthorship W4361954246A5033440492 @default.
• W4361954246 hasAuthorship W4361954246A5043864217 @default.
• W4361954246 hasAuthorship W4361954246A5049910941 @default.
• W4361954246 hasAuthorship W4361954246A5052288829 @default.
• W4361954246 hasAuthorship W4361954246A5054876564 @default.
• W4361954246 hasAuthorship W4361954246A5056577241 @default.
• W4361954246 hasAuthorship W4361954246A5058612163 @default.
• W4361954246 hasAuthorship W4361954246A5062167990 @default.
• W4361954246 hasAuthorship W4361954246A5062542207 @default.
• W4361954246 hasAuthorship W4361954246A5062941900 @default.
• W4361954246 hasAuthorship W4361954246A5064201088 @default.
• W4361954246 hasAuthorship W4361954246A5079310177 @default.
• W4361954246 hasAuthorship W4361954246A5088347458 @default.
• W4361954246 hasBestOaLocation W43619542462 @default.
• W4361954246 hasConcept C121332964 @default.
• W4361954246 hasConcept C121608353 @default.
• W4361954246 hasConcept C126322002 @default.
• W4361954246 hasConcept C142424586 @default.
• W4361954246 hasConcept C197934379 @default.
• W4361954246 hasConcept C2775949291 @default.
• W4361954246 hasConcept C2777701055 @default.
• W4361954246 hasConcept C2777928532 @default.
• W4361954246 hasConcept C2778375690 @default.
• W4361954246 hasConcept C2780007613 @default.
• W4361954246 hasConcept C2780057760 @default.
• W4361954246 hasConcept C2780240888 @default.
• W4361954246 hasConcept C2780817109 @default.
• W4361954246 hasConcept C29730261 @default.
• W4361954246 hasConcept C31760486 @default.
• W4361954246 hasConcept C71924100 @default.
• W4361954246 hasConcept C87355193 @default.
• W4361954246 hasConcept C90924648 @default.
• W4361954246 hasConceptScore W4361954246C121332964 @default.
• W4361954246 hasConceptScore W4361954246C121608353 @default.
• W4361954246 hasConceptScore W4361954246C126322002 @default.
• W4361954246 hasConceptScore W4361954246C142424586 @default.
• W4361954246 hasConceptScore W4361954246C197934379 @default.
• W4361954246 hasConceptScore W4361954246C2775949291 @default.
• W4361954246 hasConceptScore W4361954246C2777701055 @default.
• W4361954246 hasConceptScore W4361954246C2777928532 @default.
• W4361954246 hasConceptScore W4361954246C2778375690 @default.
• W4361954246 hasConceptScore W4361954246C2780007613 @default.
• W4361954246 hasConceptScore W4361954246C2780057760 @default.
• W4361954246 hasConceptScore W4361954246C2780240888 @default.
• W4361954246 hasConceptScore W4361954246C2780817109 @default.
• W4361954246 hasConceptScore W4361954246C29730261 @default.
• W4361954246 hasConceptScore W4361954246C31760486 @default.
• W4361954246 hasConceptScore W4361954246C71924100 @default.
• W4361954246 hasConceptScore W4361954246C87355193 @default.
• W4361954246 hasConceptScore W4361954246C90924648 @default.
• W4361954246 hasLocation W43619542461 @default.
• W4361954246 hasLocation W43619542462 @default.
• W4361954246 hasOpenAccess W4361954246 @default.
• W4361954246 hasPrimaryLocation W43619542461 @default.
• W4361954246 hasRelatedWork W2751463181 @default.
• W4361954246 hasRelatedWork W2914806773 @default.
• W4361954246 hasRelatedWork W2943259648 @default.

• next